In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series G raises $38mm for Broncus Technologies

Executive Summary

A few months after withdrawing its IPO, emphysema device developer Broncus Technologies is looking to venture capital again, raising $38mm in its Series G round led by first-time backer Ares Life Sciences, which put in $25mm and contributes a new board member. Also participating were existing investors including Abingworth, Bio*One, Charter Ventures, HBM BioVentures, JAIC America, Menlo Ventures, Pac-Link Ventures, Saints Capital, and Sightline Ventures. Broncus will use the money to complete the pivotal clinical trial for its minimally invasive Airway Bypass procedure, which helps release trapped air in the lungs.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies